Bluejay Diagnostics Nears Completion of Pivotal Sepsis Trial Enrollment

Event summary

  • Bluejay Diagnostics has enrolled 624 patients in its SYMON-II pivotal clinical trial, targeting 750 total.
  • The trial evaluates the Symphony™ IL-6 test for sepsis triage and monitoring in critical care settings.
  • Enrollment completion is expected within 2-3 months, with no significant patient exclusions due to criteria.
  • The study aims to support a 510(k) application to the FDA for regulatory clearance.

The big picture

Bluejay's progress in the SYMON-II trial underscores the growing emphasis on rapid, point-of-care diagnostics in critical care. The Symphony™ IL-6 test, if successfully validated, could address a significant unmet need in sepsis triage, where timely intervention is critical. The company's focus on regulatory clearance positions it to compete in a market increasingly prioritizing real-time monitoring solutions.

What we're watching

Regulatory Pathway
The pace at which Bluejay advances toward FDA submission and clearance for the Symphony™ IL-6 test.
Clinical Validation
Whether the remaining patient enrollments confirm the trial's initial positive trends.
Market Adoption
How rapid, near-patient testing for sepsis triage could reshape critical care decision-making.

Related topics

Clinical Trial